(Q36967178)

17 August 2017

1 reference

title

Maraviroc (English)

1 reference

17 August 2017

2

Gillian M Keating

1 reference

17 August 2017

Natalie J Carter

1

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

67

1 reference

17 August 2017

issue

15

1 reference

17 August 2017

page(s)

2277-88; discussion 2289-90

1 reference

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

17 August 2017

cites work

1 reference

12 December 2020

Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists

1 reference

12 December 2020

Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.

1 reference

12 December 2020

The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.

1 reference

12 December 2020

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

1 reference

12 December 2020

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

1 reference

12 December 2020

A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc

1 reference

12 December 2020

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

12 December 2020

HIV type 1 tropism and inhibitors of viral entry: clinical implications.

1 reference

12 December 2020

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

1 reference

12 December 2020

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

12 December 2020

10.2165/00003495-200767150-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1046700440

0 references

1 reference